Eisana

Executive Summary

Eisana Health is a digital health company developing a patient-administered cooling device to prevent chemotherapy-induced peripheral neuropathy (CIPN), a debilitating side effect affecting up to 68% of patients on neurotoxic chemotherapy. Unlike existing cryotherapy solutions that require clinical supervision, Eisana's device is designed for independent use at home, enabling continuous neuroprotection while maintaining hand and foot function during treatment. By integrating AI-driven temperature control and real-time monitoring, the device aims to improve adherence and patient outcomes while reducing the burden on healthcare systems. Although still in early stages (no disclosed funding or clinical milestones), the company addresses a significant unmet need, as no FDA-approved preventive therapy for CIPN currently exists. Its focus on patient-centric design and home-based care positions it well within the growing digital health and supportive oncology markets.

Upcoming Catalysts (preview)

• Q1 2027First-in-human clinical trial results60% success
• Q2 2027FDA breakthrough device designation50% success
• Q4 2026Strategic partnership with a major cancer center or pharma company40% success